GSA Capital Partners LLP Acquires 26,651 Shares of PROCEPT BioRobotics Corporation $PRCT

GSA Capital Partners LLP boosted its holdings in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 400.2% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 33,310 shares of the company’s stock after acquiring an additional 26,651 shares during the quarter. GSA Capital Partners LLP owned 0.06% of PROCEPT BioRobotics worth $1,189,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the business. M&G PLC lifted its position in shares of PROCEPT BioRobotics by 3.3% during the third quarter. M&G PLC now owns 148,331 shares of the company’s stock worth $5,340,000 after purchasing an additional 4,772 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in PROCEPT BioRobotics by 93.4% in the 3rd quarter. PNC Financial Services Group Inc. now owns 9,128 shares of the company’s stock worth $326,000 after buying an additional 4,408 shares during the period. Alps Advisors Inc. lifted its holdings in PROCEPT BioRobotics by 64.8% during the 3rd quarter. Alps Advisors Inc. now owns 22,523 shares of the company’s stock valued at $804,000 after buying an additional 8,854 shares in the last quarter. C WorldWide Group Holding A S purchased a new stake in PROCEPT BioRobotics in the 3rd quarter valued at about $5,354,000. Finally, Bessemer Group Inc. grew its stake in PROCEPT BioRobotics by 36.0% in the 3rd quarter. Bessemer Group Inc. now owns 24,930 shares of the company’s stock worth $890,000 after acquiring an additional 6,595 shares in the last quarter. Institutional investors own 89.46% of the company’s stock.

PROCEPT BioRobotics Stock Performance

PRCT opened at $27.72 on Thursday. The company has a market cap of $1.55 billion, a P/E ratio of -18.12 and a beta of 0.99. The company has a quick ratio of 7.20, a current ratio of 8.44 and a debt-to-equity ratio of 0.14. The firm’s 50-day moving average price is $31.18 and its 200-day moving average price is $34.30. PROCEPT BioRobotics Corporation has a 52-week low of $26.66 and a 52-week high of $70.80.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Bank of America reiterated a “neutral” rating and issued a $38.00 price target (down previously from $55.00) on shares of PROCEPT BioRobotics in a report on Monday, December 8th. Truist Financial lowered their target price on PROCEPT BioRobotics from $50.00 to $47.00 and set a “buy” rating for the company in a report on Thursday, December 18th. Piper Sandler restated an “overweight” rating and set a $50.00 price target (down previously from $55.00) on shares of PROCEPT BioRobotics in a research note on Wednesday, November 5th. TD Cowen lowered their price objective on shares of PROCEPT BioRobotics from $85.00 to $50.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $53.40.

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.